Dynavax Technologies (NASDAQ:DVAX) is up 15% after hours on light volume after Cantor Fitzgerald resumed coverage with an Overweight rating and $20 (425% upside) price target.
The company recently restructured, cutting 37% of its workforce and divesting its immuno-oncology programs, in order to focus its resources on hepatitis B vaccine HEPLISAV-B.
Shares are down almost 70% since early January.
Quant rating is Very Bearish and SA Authors rating is Neutral.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.